Disc Medicine
IRON
61.18
-0.47
-0.76%
Disc Medicine
US · IRON
#2647 by market cap
Listed 1970
61.18
-0.47
-0.76%
Live - 5344 symbols - heartbeat 510s ago
· 2026-10-08 07:13
Pre-market
60.70
-0.78%
After-hours
61.12
-0.10%
- Market cap
- 2.35B
- P/E (TTM)i
- -9.28
- P/Bi
- 3.65
- EPSi
- -6.01
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on IRON?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 6 years
Key ratios & quality
- Enterprise valuei
- 1.59B
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 5.87M | 5.76M | 14.04M | 21.86M | 33.05M | 65.38M |
| Research & development | 28.17M | 25.17M | 33.44M | 69.26M | 96.67M | 170.64M |
| Operating profit | -34.04M | -30.93M | -47.48M | -91.13M | -129.72M | -236.02M |
| Pretax profit | -40.84M | -35.97M | -46.83M | -76.33M | -109.00M | -211.82M |
| Tax | -- | -- | 0 | 99.00K | 355.00K | 361.00K |
| Net profit | -40.84M | -35.97M | -46.83M | -76.43M | -109.36M | -212.18M |
| Basic EPS | -9 | -41 | -45 | -3 | -4 | -6 |
| Diluted EPS | -9.01 | -40.95 | -45.05 | -3.42 | -3.96 | -6.01 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 12.18M | 15.09M | 17.36M | 20.75M | 23.62M | 18.14M |
| Research & development | 27.76M | 46.32M | 50.33M | 46.22M | 45.90M | 46.93M |
| Operating profit | -39.95M | -61.41M | -67.70M | -66.97M | -69.52M | -65.08M |
| Pretax profit | -33.97M | -55.20M | -62.22M | -60.44M | -63.45M | -59.46M |
| Tax | 119.00K | 52.00K | 102.00K | 88.00K | 51.00K | 69.00K |
| Net profit | -34.09M | -55.25M | -62.32M | -60.53M | -63.50M | -59.53M |
| Basic EPS | -1 | -2 | -2 | -2 | -2 | -2 |
| Diluted EPS | -1.02 | -1.58 | -1.77 | -1.62 | -1.65 | -1.54 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 5.07M | 90.48M | 198.49M | 365.66M | 493.62M | 803.90M |
| Cash & ST investments | 4.50M | 88.04M | 194.61M | 360.38M | 489.88M | 791.15M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 8.32M | 92.41M | 200.21M | 368.00M | 496.77M | 806.88M |
| Total current liabilities | 24.88M | 13.42M | 22.58M | 21.44M | 23.32M | 36.64M |
| Short-term debt | 16.69M | 319.00K | 307.00K | 665.00K | 130.00K | 611.00K |
| Long-term debt | 4.95M | -- | -- | -- | 28.32M | 29.16M |
| Total liabilities | 30,180,000.00 | 156,614,000.00 | 23,605,000.00 | 22,875,000.00 | 53,186,000.00 | 67,053,000.00 |
| Total equity | -21.86M | -64.20M | 176.60M | 345.12M | 443.59M | 739.83M |
| Retained earnings | -112.82M | -65.39M | -112.22M | -188.65M | -298.00M | -510.19M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 705.60M | 661.59M | 627.17M | 803.90M | 747.46M | 732.76M |
| Cash & ST investments | 694.66M | 649.97M | 615.92M | 791.15M | 730.16M | 717.75M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 709.27M | 665.06M | 630.46M | 806.88M | 750.21M | 735.07M |
| Total current liabilities | 18.74M | 20.61M | 26.74M | 36.64M | 31.14M | 30.36M |
| Short-term debt | 479.00K | 632.00K | 656.00K | 611.00K | 419.00K | 315.00K |
| Long-term debt | 28.53M | 28.74M | 28.95M | 29.16M | 29.37M | 59.34M |
| Total liabilities | 48,904,000.00 | 50,896,000.00 | 57,066,000.00 | 67,053,000.00 | 61,784,000.00 | 90,907,000.00 |
| Total equity | 660.36M | 614.17M | 573.39M | 739.83M | 688.43M | 644.16M |
| Retained earnings | -332.09M | -387.33M | -449.66M | -510.19M | -573.69M | -633.22M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -32.71M | -27.53M | -42.25M | -73.46M | -93.93M | -180.39M |
| Depreciation & amortization | 322.00K | 32.00K | 89.00K | 100.00K | 156.00K | 281.00K |
| Free cash flow | -32.73M | -27.60M | -42.40M | -73.55M | -94.43M | -181.33M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 53.50M | 199.08M | 187.30M | 450.11M |
| Ending cash balance | 4.83M | 88.21M | 194.79M | 360.62M | 192.67M | 91.39M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -41.38M | -47.92M | -47.80M | -43.30M | -62.24M | -44.20M |
| Depreciation & amortization | 20.00K | 85.00K | 87.00K | 89.00K | 89.00K | 90.00K |
| Free cash flow | -42.23M | -47.95M | -47.83M | -43.32M | -62.24M | -44.20M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 234.00M | 0 | 9.77M | 206.34M | 0 | 0 |
| Ending cash balance | 122.91M | 127.58M | 140.90M | 91.39M | 89.16M | 98.92M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -34.82 | -59.37 | -31.07 | -29.30 | -27.73 | -35.86 |
| ROA %i | -33.45 | -54.75 | -27.49 | -26.90 | -25.29 | -32.55 |
| ROIC %i | -29.03 | -55.14 | -30.85 | -34.74 | -30.63 | -37.17 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 0.20 | 6.74 | 8.79 | 17.06 | 21.17 | 21.94 |
| Quick ratioi | 0.18 | 6.56 | 8.62 | 16.81 | 21.01 | 21.59 |
| Debt / assetsi | 260.13 | 1.79 | 0.67 | 0.57 | 6.04 | 3.84 |
| LT debt / equityi | -- | -- | 0.58 | 0.42 | 6.73 | 4.11 |
| Interest coveragei | -4.98 | -32.30 | -- | -- | -189.56 | -57.73 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 0.00 | 0.00 | 0.00 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -23.34 | -26.36 | -34.78 | -35.86 | -35.83 | -39.08 |
| ROA %i | -21.91 | -24.74 | -32.18 | -32.55 | -33.11 | -35.12 |
| ROIC %i | -26.00 | -28.91 | -37.09 | -37.17 | -36.32 | -38.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 37.65 | 32.11 | 23.45 | 21.94 | 24.00 | 24.14 |
| Quick ratioi | 37.07 | 31.54 | 23.03 | 21.59 | 23.45 | 23.64 |
| Debt / assetsi | 4.32 | 4.65 | 4.91 | 3.84 | 4.14 | 8.28 |
| LT debt / equityi | 4.57 | 4.93 | 5.29 | 4.11 | 4.45 | 9.40 |
| Interest coveragei | -77.98 | -59.92 | -53.81 | -57.73 | -66.90 | -68.14 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Quote time 2026-10-08 07:13:37 · For reference only, not investment advice and not tailored to your situation.